ArticleAAPS PharmSciTech2015
Solid-State and Solution Characterization of Myricetin.
Article in AAPS PharmSciTech, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 27 citations in OpenAlex.
- Comparative Evaluation of the Antioxidant Capacities of Commonly Consumed Dietary Polyphenols.Molecules (Basel, Switzerland) · 2026Article
- Discovery of new bioactive secondary metabolites from the stem bark of oroxylum indicum: isolation, structural identification, antimicrobial and cytotoxicity assessment.Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents · 2026Article
- Myricetin Nanofibers as Amorphous Delivery System.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Complementary antioxidant strategy for diabetic wound healing: myricetin and ceria nanozymes for enhanced reactive oxygen species management.Regenerative biomaterials · 2026Article
- Thermal Characterization and Heat Capacities of Seven Polyphenols.Molecules (Basel, Switzerland) · 2025Article
- Myricetin Amorphous Solid Dispersions-Antineurodegenerative Potential.Molecules (Basel, Switzerland) · 2024Article
- Flavonoids in the Spotlight: Bridging the Gap between Physicochemical Properties and Formulation Strategies.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Polyphenol-Hydroxylating Tyrosinase Activity under Acidic pH Enables Efficient Synthesis of Plant Catechols and Gallols.Microorganisms · 2021Article
- Flavonoids with Glutathione Antioxidant Synergy: Influence of Free Radicals Inflow.Antioxidants (Basel, Switzerland) · 2020Article
- Solubility Enhancement of Myricetin by Inclusion Complexation with Heptakis-International journal of molecular sciences · 2020Article
- New micelle myricetin formulation for ocular delivery: improved stability, solubility, and ocular anti-inflammatory treatment.Drug delivery · 2019Article
- Enhanced Protection of Biological Membranes during Lipid Peroxidation: Study of the Interactions between Flavonoid Loaded Mesoporous Silica Nanoparticles and Model Cell Membranes.International journal of molecular sciences · 2019Article
- Chemoprevention of intestinal tumorigenesis by the natural dietary flavonoid myricetin in APCMin/+ mice.Oncotarget · 2016Article
- Estimating the Aqueous Solubility of Pharmaceutical Hydrates.Journal of pharmaceutical sciences · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Myricetin (MYR) is a natural compound that has been investigated as a chemopreventative agent. MYR has been shown to suppresses ultraviolet B (UVB)-induced cyclooxygenase-2 (COX-2) protein expression and reduce the incidence of UVB-induced skin tumors in mice. Despite MYR's promise as a therapeutic agent, minimal information is available to guide the progression of formulations designed for future drug development. Here, data is presented describing the solid-state and solution characterization of MYR. Investigation into the solid-state properties of MYR identified four different crystal forms, two hydrates (MYR I and MYR II) and two metastable forms (MYR IA and MYR IIA). From solubility studies, it was evident that all forms are very insoluble (<5 μg/ml) in pure water. MYR I was found to be the most stable form at 23, 35, and 56°C. Stability determination indicated that MYR undergoes rapid apparent first-order degradation under basic pH conditions, and that degradation was influenced by buffer species. Apparent first-order degradation was also seen when MYR was introduced to an oxidizing solution. Improved stability was achieved after introducing 0.1% antioxidants to the solution. MYR was found to have good stability following exposure to ultraviolet radiation (UVR), which is a consideration for topical applications. Finally, a partitioning study indicated that MYR possess a log P of 2.94 which, along with its solid-state properties, contributes to its poor aqueous solubility. Both the solid-state properties and solution stability of MYR are important to consider when developing future formulations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.